Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

I Chen; K L Wind; C Dehlendorff; B S Sørensen; B V Vittrup; A Johansen; P Pfeiffer; J K Bjerregaard; S E Bojesen; S E Nielsen; N H Holländer; M K Yilmaz; L S Rasmussen; N Pallisgaard; J S Johansen; K-L G Spindler

doi:10.1093/annonc/mdy282.098

Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

I Chen, K L Wind, C Dehlendorff, B S Sørensen, B V Vittrup, A Johansen, P Pfeiffer, J K Bjerregaard, S E Bojesen, S E Nielsen, N H Holländer, M K Yilmaz, L S Rasmussen, N Pallisgaard, J S Johansen, K-L G Spindler

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

15 Citations (Scopus)

Abstract

Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

Original language	English
Article number	715P
Journal	Annals of Oncology
Volume	29
Issue number	suppl_8
Pages (from-to)	vii241-vii242
Number of pages	2
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdy282.098
Publication status	Published - Oct 2018
Event	ESMO 2018 Congress (European Society for Medical Oncology): Securing access to optimal cancer care - München, Germany Duration: 19 Oct 2018 → 23 Oct 2018 http://www.esmo.org/Conferences/ESMO-2018-Congress

Conference

Conference	ESMO 2018 Congress (European Society for Medical Oncology)
Country/Territory	Germany
City	München
Period	19/10/2018 → 23/10/2018
Internet address	http://www.esmo.org/Conferences/ESMO-2018-Congress

Access to Document

10.1093/annonc/mdy282.098

https://academic.oup.com/annonc/article/29/suppl_8/mdy282.098/5141571

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Chen, I., Wind, K. L., Dehlendorff, C., Sørensen, B. S., Vittrup, B. V., Johansen, A., Pfeiffer, P., Bjerregaard, J. K., Bojesen, S. E., Nielsen, S. E., Holländer, N. H., Yilmaz, M. K., Rasmussen, L. S., Pallisgaard, N., Johansen, J. S., & Spindler, K.-L. G. (2018). Clinical utility of plasma cell-free DNA in patients with pancreatic cancer. Annals of Oncology, 29(suppl_8), vii241-vii242. Article 715P. https://doi.org/10.1093/annonc/mdy282.098

@article{223ae55883634d4f9b6d0836044a2717,

title = "Clinical utility of plasma cell-free DNA in patients with pancreatic cancer",

abstract = "Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.",

author = "I Chen and Wind, {K L} and C Dehlendorff and S{\o}rensen, {B S} and Vittrup, {B V} and A Johansen and P Pfeiffer and Bjerregaard, {J K} and Bojesen, {S E} and Nielsen, {S E} and Holl{\"a}nder, {N H} and Yilmaz, {M K} and Rasmussen, {L S} and N Pallisgaard and Johansen, {J S} and Spindler, {K-L G}",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdy282.098",

language = "English",

volume = "29",

pages = "vii241--vii242",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "suppl_8",

note = "ESMO 2018 Congress (European Society for Medical Oncology) ; Conference date: 19-10-2018 Through 23-10-2018",

url = "http://www.esmo.org/Conferences/ESMO-2018-Congress",

}

Chen, I, Wind, KL, Dehlendorff, C, Sørensen, BS, Vittrup, BV, Johansen, A, Pfeiffer, P, Bjerregaard, JK, Bojesen, SE, Nielsen, SE, Holländer, NH, Yilmaz, MK, Rasmussen, LS, Pallisgaard, N, Johansen, JS & Spindler, K-LG 2018, 'Clinical utility of plasma cell-free DNA in patients with pancreatic cancer', Annals of Oncology, vol. 29, no. suppl_8, 715P, pp. vii241-vii242. https://doi.org/10.1093/annonc/mdy282.098

TY - ABST

T1 - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

AU - Chen, I

AU - Wind, K L

AU - Dehlendorff, C

AU - Sørensen, B S

AU - Vittrup, B V

AU - Johansen, A

AU - Pfeiffer, P

AU - Bjerregaard, J K

AU - Bojesen, S E

AU - Nielsen, S E

AU - Holländer, N H

AU - Yilmaz, M K

AU - Rasmussen, L S

AU - Pallisgaard, N

AU - Johansen, J S

AU - Spindler, K-L G

PY - 2018/10

Y1 - 2018/10

N2 - Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

AB - Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

U2 - 10.1093/annonc/mdy282.098

DO - 10.1093/annonc/mdy282.098

M3 - Conference abstract in journal

SN - 0923-7534

VL - 29

SP - vii241-vii242

JO - Annals of Oncology

JF - Annals of Oncology

IS - suppl_8

M1 - 715P

T2 - ESMO 2018 Congress (European Society for Medical Oncology)

Y2 - 19 October 2018 through 23 October 2018

ER -